Company Overview of MORPHOTEK INC.
MORPHOTEK INC. researches and develops a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of ovarian cancer, nonsmall cell lung cancer, melanoma, colorectal carcinoma, sarcoma, mesothelioma, inflammatory disease, and rheumatoid arthritis. The company’s products pipeline includes Farletuzumab, an investigational humanized IgG1 antibody that targets folate receptor alpha; Amatuximab, an investigational chimeric IgG1 antibody that targets mesothelin; Ontuxizumab, an investigational monoclonal antibody that recognizes endosialin; MORAb-022, an investigational human IgG1 monoclonal antibody that is investigated for its potential in the treatment of various inflam...
210 Welsh Pool Road
Exton, PA 19341
Founded in 1999
Key Executives for MORPHOTEK INC.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Chief Finance Officer and Vice President of Project Management
Vice President of Pilot Plant Operations
Compensation as of Fiscal Year 2015.
MORPHOTEK INC. Key Developments
Morphotek, Inc. Announces License Agreement with Biocare Medical, LLC to Develop, Commercialize Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Dec 16 15
Morphotek Inc. announced that it entered into a second collaboration and license agreement with Biocare Medical, LLC (Biocare) to develop and commercialize an immunohistochemical (IHC) diagnostic kit utilizing Morphotek's proprietary monoclonal antibody to specifically detect mesothelin with Biocare's intelliPATH Automated Stainer. The agreement provides Biocare with a worldwide non-exclusive license to develop, manufacture and commercialize an IHC kit for detection of mesothelin on formalin-fixed paraffin-embedded (FFPE) tumor tissues. This is the second such agreement between Morphotek and Biocare; the first a license agreement signed in 2011 to develop kits, now commercially available, to detect folate receptor alpha in malignant tissues. Mesothelin is a cell-surface protein that is over-expressed in a variety of cancers including mesothelioma, non-small cell lung adenocarcinoma, pancreatic and ovarian carcinoma. Studies have found its expression variable among different cancer types; therefore, diagnostic assays that can identify patients with mesothelin-positive cancers may enable better diagnosis and treatment options for patients affected with mesothelin-expressing cancers. Mesothelin is the target of Morphotek's investigational therapeutic candidate, amatuximab, which is currently being assessed in a randomized, double-blind clinical trial in patients with newly diagnosed malignant pleural mesothelioma.
Morphotek, Inc. Announces Results from Study MORAb-022-001
Dec 7 15
Morphotek Inc. announced results from Study MORAb-022-001, a single-dose, dose-ascending, placebo-controlled, Phase 1 trial evaluating the safety and tolerability of its investigational, anti-GM-CSF, monoclonal antibody, MORAb-022 in healthy subjects (n=26) and mild-to-moderate Rheumatoid Arthritis (RA) patients (n=25). In this study, all of the MORAb-022 dose cohorts in the RA patients demonstrated decreases in their median 28-joint Disease Activity Score based on C-reactive protein (DAS28 (CRP)) by Day 5; however, only the higher single-dosed 10 mg/kg cohort showed a median decrease of more than 1.2 units, which is considered clinically meaningful according to the European League Against Rheumatism (EULAR). The overall incidence of Treatment Emergent Adverse Events was low, and there were no severe adverse events reported during the study for any subject. There were no Rheumatology Common Toxicity Criteria (RCTC) Grade 3 or 4 adverse events reported for subjects with RA in any dose cohort during the study. The pharmacokinetics for MORAb-022 increased approximately in a linear, dose-proportional manner.
Morphotek, Inc. Announces Collaboration Agreement with University of Wisconsin-Madison
Dec 3 15
Morphotek Inc., a subsidiary of Eisai Inc. announced that it entered into a collaborative research agreement with University of Wisconsin-Madison to elucidate the immunosuppressive effects of the CA125 tumor antigen on the investigational monoclonal antibody farletuzumab. Farletuzumab is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha (FRA), a cell-surface protein highly expressed in ovarian carcinoma but largely absent from normal tissue. The collaboration will initially investigate the immune status of primary macrophage and NK cells derived from the blood of ovarian cancer patients with varying levels of CA125. In addition, the collaboration will test whether the farletuzumab-mediated killing of ovarian cancer cells using patient-derived immune cells is affected by tumor-derived CA125.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|